State Street’s AN2 Therapeutics ANTX Stock Holding History

State Street’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$394K	Buy	115,202 +28,200	+32%	+$58.2K	﹤0.01%	3716
2025 Q4	$99.2K	Hold	87,002	–	–	﹤0.01%	4049
2025 Q3	$110K	Hold	87,002	–	–	﹤0.01%	4034
2025 Q2	$92.2K	Hold	87,002	–	–	﹤0.01%	3989
2025 Q1	$118K	Hold	87,002	–	–	﹤0.01%	3937
2024 Q4	$120K	Buy	87,002 +26,700	+44%	+$32.4K	﹤0.01%	3957
2024 Q3	$64.5K	Hold	60,302	–	–	﹤0.01%	4055
2024 Q2	$130K	Hold	60,302	–	–	﹤0.01%	3932
2024 Q1	$196K	Buy	60,302 +22,000	+57%	+$239K	﹤0.01%	3877
2023 Q4	$785K	Buy	38,302 +22,900	+149%	+$383K	﹤0.01%	3529
2023 Q3	$248K	Sell	15,402 -2,700	-15%	-$30.6K	﹤0.01%	3871
2023 Q2	$154K	Sell	18,102 -78,782	-81%	-$566K	﹤0.01%	4086
2023 Q1	$956K	Buy	96,884 +5,862	+6%	+$65.2K	﹤0.01%	3546
2022 Q4	$867K	Buy	91,022 +37,341	+70%	+$500K	﹤0.01%	3591
2022 Q3	$933K	Buy	53,681 +8,459	+19%	+$98.6K	﹤0.01%	3609
2022 Q2	$350K	Buy	+45,222	New	+$599K	﹤0.01%	3977

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street's ANTX Position: Q1 2026 in Review

State Street increased its AN2 Therapeutics (ANTX) stake by 32% in Q1 2026, buying an estimated $58.2K and bringing the position to 115,202 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #3716.

State Street first reported a position in ANTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $956K in Q1 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

State Street held 115,202 shares of AN2 Therapeutics worth $394K as of Q1 2026.
State Street bought 28,200 AN2 Therapeutics shares in Q1 2026, an estimated $58.2K.
AN2 Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3716 holding.
State Street first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 16 quarters since.
State Street's AN2 Therapeutics position peaked at $956K in Q1 2023.
52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.